Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsWebMD EducationNovember 27, 2019Mystery Solved: New Research Reveals Why a Key Protein Turns Deadly in Aging BodiesFebruary 26, 2025BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)July 17, 2023 Previous post2026 Winter NewsletterNext postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis